source
- Phase 3 trial shows Zealand-Boehringer obesity drug survodutide does not raise cardiovascular death riskThe Phase 3 SYNCHRONIZE-CVOT study found that survodutide, the joint obesity therapy from Zealand and Boehringer Ingelheim, was non‑inferior to placebo for cardiovascular death, indicating no added…
- Gene therapy sponsors urged to address six GMP manufacturing considerations earlySK pharmteco’s chief technical officer Tatiana Nanda explained that gene therapy sponsors need to think about manufacturing issues well before reaching GMP production. She told BioSpace that early…